HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 drugs linked to halved 5-year death in obese colon cancer patients

Louis Nervegna · Nov 25, 2025 · ♥ 5 reactions · 1 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Cancer
AI summary & key facts

Medscape reports a real-world analysis of nearly 7,000 colon cancer patients in which those on a GLP-1 receptor agonist were less than half as likely to die within 5 years. Louis links this to calorie restriction effects seen in animals.

GLP-1 agonists may increase survival in colon cancer patients.

(We’ve known for a long time that calorie restriction slows growth of various cancers in animal models.)

#glp1HD #coloncancerHD

Research cited

Shared from Medscape · original post

Treatment with a GLP-1 receptor agonist (RA) may offer a survival advantage in patients with colon cancer and obesity.

In a real-world analysis of nearly 7000 patients with colon cancer, those taking a GLP-1 RA were less than half as likely to die within 5 years compared with those who weren’t on a GLP-1 drug. GLP-1s May Improve Colon Cancer Outcomes (Medscape)

No photo description available.
← newer: CARBFUNC RCT: low-carb and whole-food high-carb diets both colder: Roy Taylor's trial: clearing liver and pancreas fat puts typ →